hVIVO (HVO:7.75p) has announced a significant contract cancellation alongside a postponement and a smaller study cancellation that has led to material earnings downgrades. The company is a specialist ...

Dan Jones and the IC team unpack results from a retailer, what investors can learn from 25 years of volatility, and the ...

Sensibly, management has been carefully managing costs and is maintaining tight control over working capital. Net cash ...

Takeovers and mergers are a natural part of life on the market. It makes sense for companies to buy or merge with competitors ...

Arguably, one company that fits this description is speciality polymers manufacturer Victrex (VCT), which is the world’s ...

The figures for the year to 31 March were in line with the prior warning. Revenue grew 1 per cent (2 per cent organically) to £1.93bn, with growth driven by the UK and Australia as US sales fell 13 ...

Having recently appointed a new chief executive, Raffi Stepanian, the medical technology company is building real sales ...

Led by a team who made their name at turnaround specialist Hilco, the group is acquiring undervalued SME businesses at favourable prices by providing an exit to their founders. Moreover, by focusing ...

While it may not have the glamour, or the ratings, of its near(ish) cousin, the technology sector, this is still a dynamic, operational & geographically diverse sector where many stocks have long ...

We mentioned yesterday that the coming weeks would be challenging for traders, with the potential for tariff delays, new tariffs, and posts on TruthSocial all sending shares in both directions. Well, ...

Five months into an unsettling year for markets, the Bearbull Income Portfolio is up by 3.3 per cent.

The US drugmaker has stolen a march on Novo Nordisk by bringing a viable oral weight-loss medicine, orforglipron, into successful phase 3 clinical trials. An oral version is the holy grail for drugs ...